ReviewConsortium psychiatricum2024
Comparison of Immune and Systemic Inflammation Parameters in Patients with a Depressive Episode in Bipolar Disorder and Major Depressive Disorder: A Scoping Review.
Review in Consortium psychiatricum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Lactate metabolism regulation enhances cuproptosis to activate antitumor immunity: Synergistic therapy of hyaluronic acid nanomicelles delivering lactate oxidase/copper-doped carbon dots combined with α-PD-L1 inhibits distant tumors.Materials today. Bio · 2026Article
- Nonlinear associations of plasma IL-9 with depression and anxiety symptoms in first-episode, drug-naïve major depressive disorder.European archives of psychiatry and clinical neuroscience · 2026Article
- Differentiating Between Major Depressive Disorder and Bipolar Disorder.Advances in experimental medicine and biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany studies have aimed to investigate and compare immune system and systemic inflammation parameters in patients with bipolar disorder (BD) and major depressive disorder (MDD) suffering from a depressive episode. However, no systematic review of the results has been conducted so far.
aimThe aim of this study was to conduct a scoping review of research studies comparing immune and systemic inflammation parameters in patients with BD and MDD during a depressive episode.
methodsThe search for studies was conducted in the Medline and eLIBRARY databases for the period from January 1994 to December 2022. Open-access articles written in English and Russian were selected. The review included original studies that compared groups of patients with BD and MDD (diagnosed based on the DSM-IV, DSM-5, or ICD-10 criterion) by immune and systemic inflammation parameters (such as the counts, ratio, and functions of blood cells, erythrocyte sedimentation rate, concentrations of immunoglobulins, cytokines, acute phase proteins, complement components, and autoantibodies).
resultsThe review included 24 studies. Current depressive episodes in patients with BD were associated with higher concentrations of chemokines (C-C motif chemokine ligand 3 (CCL3), CCL4, CCL5, CCL11), platelet-derived growth factor B, and interleukin 9 (IL-9) (two studies in each case), whereas patients with MDD tended to have higher concentrations of soluble tumor necrosis factor receptor 1 and immunoglobulin G to oxidized low-density lipoproteins (two studies each). Patients with BD and MDD had comparable concentrations of IL-8 (five studies); IL-2 and IL-10 (four studies each); IL-13 and gamma interferon (three studies each); IL-17, IL-1Rα, the vascular endothelial growth factor, as well as white blood cells, monocyte, and platelet counts (two studies each). Contradictory results were obtained for the levels of tumor necrosis factor-α (the concentrations did not differ in five studies, were elevated in BD patients in five studies, were elevated in MDD patients in two studies), IL-6 (the concentrations did not differ in eight studies and were elevated in BD patients in four studies), C-reactive protein (the concentrations did not differ in six studies, were elevated in BD patients in two studies), IL-4 (the concentrations did not differ in three studies and were elevated in MDD patients in two studies), IL-1β and the neutrophil count (the levels did not differ in one study each and were elevated in BD patients in two studies). Several studies have demonstrated an association between immune and systemic inflammation parameters and the severity of depressive and anxiety symptoms, melancholic depression, age of mood disorder onset, body mass index, and imipramine equivalent.
conclusionSome immune and systemic inflammation parameters are associated with a current depressive episode in patients with MDD or BD. These parameters may be considered as potential biomarkers for a differential diagnosis of these disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.